Clinical Trial Update: DP303c in Patients With HER2-positive Unresectable Locally Advanced, Relapsed, or Metastaticbreast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update for DP303c in HER2-positive unresectable locally advanced, relapsed, or metastatic breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• DP303c (DP303c)

Snippet

Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Conditions: HER2-positive Breast Cancer | Phase 2 | Status: UNKNOWN